Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.